Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Intervalo de año de publicación
1.
Rev. chil. pediatr ; 91(6): 982-990, dic. 2020. ilus, tab
Artículo en Español | LILACS | ID: biblio-1508061

RESUMEN

Desde la aparición de la pandemia por SARS-CoV-2, la población pediátrica ha sido menos afectada por la enfermedad tanto en frecuencia como en severidad. Sin embargo, desde abril de este año se han reportado casos de presentación y gravedad variables, caracterizados por fenómenos inflamato rios que afectan múltiples órganos, condición denominada Síndrome Inflamatorio Multisistémico Pediátrico (PIMS). La literatura describe frecuente compromiso cardíaco, hasta en un 80%. Este se caracteriza por injuria miocárdica con significativa elevación de biomarcadores: Troponinas séricas I/T, BNP o NT-ProBNP, unido a diversos grados de disfunción ventricular, pericarditis, valvulitis y arritmias. Además, se ha evidenciado la presencia de compromiso coronario el cual puede ocurrir hasta en un 23% de los casos, en un rango que va desde dilataciones hasta aneurismas. El seguimien to cardiológico hospitalizado y ambulatorio se ha sistematizado en base a los fenotipos clínicos de presentación: injuria miocárdica (miocarditis, valvulitis, pericarditis), shock (habitualmente de tipo "vasopléjico"), manifestaciones tipo Enfermedad de Kawasaki y aquellos casos PIMS que no cumplen con la clínica de los tres precedentes. Este último grupo es el que representa el mayor desafío en el cor to, mediano y seguimiento a largo plazo. Por esta razón se requiere un equipo multidisciplinario para su manejo. Considerando la alta frecuencia del compromiso cardíaco en el PIMS y la importancia de lograr un consenso en su manejo y seguimiento, se presentan estas recomendaciones según el estado actual del conocimiento de esta patología recientemente descrita.


Since the onset of the SARS-CoV-2 pandemic, the pediatric population has been less affected by the disease both in frequency and severity. However, since April cases of variable presentation and severity characterized by inflammatory phenomena that affect multiple organs have been reported, a condition called Multisystem Inflammatory Syndrome in Children (MIS-C). The literature has reported frequent cardiac involvement, up to 80%. This is characterized by myocardial injury with a significant increase of biomarkers such as serum troponins I and T, BNP, or NT-ProBNP coupled with varying degrees of ventricular dysfunction, pericarditis, valvulitis, and arrhythmias. Coronary compromise has also been described, which can occur in up to 23% of cases, and ranges from dila tations to aneurysms. Inpatient and outpatient cardiology follow-up has been systematized based on the clinical phenotypes such as myocardial injury (myocarditis, valvulitis, pericarditis), shock (usua lly vasoplegic), Kawasaki disease-type manifestations, and those MIS-C that do not comply with the clinic of the previous three. This last group represents the main challenge in the short-, medium- and long-term follow-up, therefore, it is necessary a multidisciplinary team for managing these patients. Considering the high frequency of cardiac compromise in MIS-C, and the importance of reaching a consensus regarding its management and follow-up, we present these recommendations according to the current state of knowledge regarding this recently described pathology.


Asunto(s)
Humanos , Niño , Enfermedades Cardiovasculares/virología , Síndrome de Respuesta Inflamatoria Sistémica/terapia , COVID-19/terapia , Grupo de Atención al Paciente/organización & administración , Choque/terapia , Choque/virología , Biomarcadores/metabolismo , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/terapia , Chile , Síndrome de Respuesta Inflamatoria Sistémica/diagnóstico , Síndrome de Respuesta Inflamatoria Sistémica/fisiopatología , COVID-19/diagnóstico , COVID-19/fisiopatología , Síndrome Mucocutáneo Linfonodular/terapia , Síndrome Mucocutáneo Linfonodular/virología
2.
Rev Chil Pediatr ; 91(6): 982-990, 2020 Dec.
Artículo en Español | MEDLINE | ID: mdl-33861837

RESUMEN

Since the onset of the SARS-CoV-2 pandemic, the pediatric population has been less affected by the disease both in frequency and severity. However, since April cases of variable presentation and severity characterized by inflammatory phenomena that affect multiple organs have been reported, a condition called Multisystem Inflammatory Syndrome in Children (MIS-C). The literature has reported frequent cardiac involvement, up to 80%. This is characterized by myocardial injury with a significant increase of biomarkers such as serum troponins I and T, BNP, or NT-ProBNP coupled with varying degrees of ventricular dysfunction, pericarditis, valvulitis, and arrhythmias. Coronary compromise has also been described, which can occur in up to 23% of cases, and ranges from dila tations to aneurysms. Inpatient and outpatient cardiology follow-up has been systematized based on the clinical phenotypes such as myocardial injury (myocarditis, valvulitis, pericarditis), shock (usua lly vasoplegic), Kawasaki disease-type manifestations, and those MIS-C that do not comply with the clinic of the previous three. This last group represents the main challenge in the short-, medium- and long-term follow-up, therefore, it is necessary a multidisciplinary team for managing these patients. Considering the high frequency of cardiac compromise in MIS-C, and the importance of reaching a consensus regarding its management and follow-up, we present these recommendations according to the current state of knowledge regarding this recently described pathology.


Asunto(s)
COVID-19/terapia , Enfermedades Cardiovasculares/virología , Síndrome de Respuesta Inflamatoria Sistémica/terapia , Biomarcadores/metabolismo , COVID-19/diagnóstico , COVID-19/fisiopatología , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/terapia , Niño , Chile , Humanos , Síndrome Mucocutáneo Linfonodular/terapia , Síndrome Mucocutáneo Linfonodular/virología , Grupo de Atención al Paciente/organización & administración , Choque/terapia , Choque/virología , Síndrome de Respuesta Inflamatoria Sistémica/diagnóstico , Síndrome de Respuesta Inflamatoria Sistémica/fisiopatología
3.
Am J Trop Med Hyg ; 74(3): 449-56, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16525106

RESUMEN

Dengue, the most prevalent arthropod-borne viral disease of humans, is caused by four serotypes of dengue virus (DENV 1-4). Although all four DENV serotypes cause a range of illness, defining precisely which clinical characteristics are associated with the distinct serotypes has been elusive. A cross-sectional study was conducted on 984 and 313 hospitalized children with confirmed DENV infections during two time periods, respectively, in the same hospitals in Nicaragua: a 3-year period (1999-2001) when DENV-2 accounted for 96% of the viruses identified, and the 2003 dengue season when DENV-1 predominated (87% of identified serotypes). When the two periods were compared, more shock (OR 1.91, 95% CI 1.35-2.71) and internal hemorrhage (OR 2.05, CI 1.16-3.78) were observed in the period when DENV-2 predominated, whereas increased vascular permeability was associated to a greater degree with the DENV-1 period (OR 2.36, CI 1.80-3.09). Compared with the DENV-2 period, the DENV-1 season was associated with more hospitalized primary dengue cases (OR 3.86, CI 2.72-5.48) and more primary DENV infections with severe manifestations (OR 2.93, CI 2.00-4.28). These findings provide new data to characterize the pathogenic potential of distinct DENV serotypes in human populations.


Asunto(s)
Virus del Dengue/crecimiento & desarrollo , Dengue/clasificación , Adolescente , Anticuerpos Antivirales/sangre , Niño , Preescolar , Estudios Transversales , Dengue/sangre , Dengue/patología , Dengue/virología , Femenino , Hematócrito , Hemorragia/patología , Hemorragia/virología , Humanos , Lactante , Masculino , Recuento de Plaquetas , Serotipificación , Choque/patología , Choque/virología , Trombocitopenia/patología , Trombocitopenia/virología
4.
Med Trop (Mars) ; 57(3 Suppl): 70-3, 1997.
Artículo en Francés | MEDLINE | ID: mdl-9513182

RESUMEN

Dengue has become a major public health problem in intertropical areas where an estimated 60 million new cases and 30,000 deaths occur annually. The causative agent is transmitted by the bite of Aedes mosquitoes which are the main and perhaps only reservoir of the disease. In addition to increasing incidence clinical manifestations of dengue have changed over the last 40 years. An increasing number of reported cases involve hemorrhage, shock, and other severe complications especially in Southeast Asia, northern regions of South America, and the Caribbean. Some of the same factors responsible for these changes are probably implicated in the development of other emerging viral diseases.


Asunto(s)
Dengue/epidemiología , Aedes/virología , Animales , Asia Sudoriental/epidemiología , Región del Caribe/epidemiología , Dengue/mortalidad , Reservorios de Enfermedades , Salud Global , Hemorragia/epidemiología , Hemorragia/virología , Humanos , Incidencia , Insectos Vectores , Salud Pública , Choque/epidemiología , Choque/virología , América del Sur/epidemiología , Clima Tropical
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA